Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease

Table 1 Studies on the discontinuation of anti-tumor necrosis factor α therapy in inflammatory bowel disease

IBD type	Anti-TNFαtherapy	n	Median follow up, mo	SCR at the end of follow up, %	Clinical benefit after re-introduction of anti-TNFαtherapy for relapse, %	Ref.
CD	IFX	115	28	55	88	[3]
CD	IFX	48	49	35	ND	[4]
CD	IFX	53	18	12	96	[7]
UC	IFX	28	29	40	71	[7]
CD	IFX or ADM	121	12	55	55	[11]
UC	IFX	51	12	65	94	[13]
CD	IFX or ADM	37	1-44 (range)	26 (1 yr)	ND	[10]
CD	IFX or ADM	17	13	71	100	[9]
UC	IFX	34	13	65	90	[9]
CD	IFX	100	120	52	ND	[6]
CD	IFX or ADM	86	17	64 (1 yr)	93	[12]
CD	IFX	92	47	28	89	[5]

IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; IFX: Infliximab; ADM: Adalimumab; TNFα: Tumor necrosis factor α; ND: Not defined; SCR: Sustained clinical remission.